Cargando…

Vortioxetine: Clinical Pharmacokinetics and Drug Interactions

Vortioxetine is a novel antidepressant with multimodal activity currently approved for the treatment of major depressive disorder. Vortioxetine is orally administered once daily at 5- to 20-mg doses. The pharmacokinetics of vortioxetine are linear and dose proportional, with a mean terminal half-lif...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Grace, Højer, Astrid-Maria, Areberg, Johan, Nomikos, George
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2017
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973995/ https://www.ncbi.nlm.nih.gov/pubmed/29189941 http://dx.doi.org/10.1007/s40262-017-0612-7

Ejemplares similares

Pharmacokinetics and Safety of Vortioxetine in the Chinese Population
por: Miao, Jia, et al.
Publicado: (2019)

Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men
por: Wilson, Sue, et al.
Publicado: (2015)

Pharmacokinetic Drug Interactions Involving Vortioxetine (Lu AA21004), a Multimodal Antidepressant
por: Chen, Grace, et al.
Publicado: (2013)

Population Pharmacokinetic Meta-Analysis of Vortioxetine in Healthy Individuals
por: Areberg, Johan, et al.
Publicado: (2014)

Pharmacokinetics and Safety of Vortioxetine in Pediatric Patients
por: Findling, Robert L., et al.
Publicado: (2017)

Lack of Effect of Vortioxetine on the Pharmacokinetics and Pharmacodynamics of Ethanol, Diazepam, and Lithium
por: Chen, Grace, et al.
Publicado: (2016)

Validation of a Population Pharmacokinetic Model of Vortioxetine Using Therapeutic Drug Monitoring Data
por: Frederiksen, Trine, et al.
Publicado: (2021)

Quantification of In Vivo Metabolic Activity of CYP2D6 Genotypes and Alleles Through Population Pharmacokinetic Analysis of Vortioxetine
por: Frederiksen, Trine, et al.
Publicado: (2020)

Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 2-week, randomized, double-blind, placebo-controlled study
por: Vieta, Eduard, et al.
Publicado: (2019)

Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 7-day randomized, double-blind, placebo-controlled exploratory study
por: Rancans, Elmars, et al.
Publicado: (2020)

The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies
por: Baldwin, David S, et al.
Publicado: (2016)

Clinical effectiveness of vortioxetine in postcovid syndrome
por: Vikarenko, M., et al.
Publicado: (2022)

A Subgroup Analysis of the Impact of Vortioxetine on Functional Capacity, as Measured by UPSA, in Patients with Major Depressive Disorder and Subjective Cognitive Dysfunction
por: Keefe, Richard S E, et al.
Publicado: (2018)

Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
por: Alvarez, Enric, et al.
Publicado: (2014)

Clinical efficacy of Vortioxetine and escitalopram in the treatment of depression
por: Shao, Shichuan, et al.
Publicado: (2022)

Neuroplasticity pathways and protein-interaction networks are modulated by vortioxetine in rodents
por: Waller, Jessica A., et al.
Publicado: (2017)

Pharmacokinetics, Safety, and Tolerability of Vortioxetine Following Single‐ and Multiple‐Dose Administration in Healthy Japanese Adults
por: Matsuno, Kumi, et al.
Publicado: (2017)

Pharmacokinetic drug-drug interaction and their implication in clinical management
por: Palleria, Caterina, et al.
Publicado: (2013)

Vortioxetine as adjunctive therapy in the treatment of schizophrenia
por: Redaelli, Sofia, et al.
Publicado: (2022)

Cognitive effects of vortioxetine in older adults: a systematic review
por: Bishop, Makenna M., et al.
Publicado: (2021)

Clinical Switching Strategies of Various Antidepressants to Vortioxetine in the PREDDICT Trial
por: Mills, Natalie T, et al.
Publicado: (2020)

Cytochrome P450 2D6 genotype–phenotype characterization through population pharmacokinetic modeling of tedatioxetine
por: Frederiksen, Trine, et al.
Publicado: (2021)

RisksAssociated with Vortioxetine in the Established Therapeutic Indication
por: Verma, Akansha, et al.
Publicado: (2021)

PS83. Impact of Vortioxetine on Functional Capacity in MDD Patients with Subjective Cognitive Dysfunction: A Post-hoc Analysis of the University of California San Diego Performance-Based Skills Assessment
por: Jacobson, William, et al.
Publicado: (2016)

Vortioxetine improves cognition in mild cognitive impairment
por: Tan, Sheng Neng, et al.
Publicado: (2021)

Which Cognitive Domains are Improved by Treatment with Vortioxetine?
por: Harrison, John E, et al.
Publicado: (2016)

Pharmacokinetic Interactions between Herbal Medicines and Drugs: Their Mechanisms and Clinical Relevance
por: Rombolà, Laura, et al.
Publicado: (2020)

Estimating the In Vivo Function of CYP2D6 Alleles through Population Pharmacokinetic Modeling of Brexpiprazole
por: Frederiksen, Trine, et al.
Publicado: (2022)

The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone
por: McIntyre, Roger S
Publicado: (2017)

Beneficial Pharmacokinetic Drug Interactions: A Tool to Improve the Bioavailability of Poorly Permeable Drugs
por: Gerber, Werner, et al.
Publicado: (2018)

Crystal structures of vortioxetine and its methanol monosolvate
por: Zhou, Xin-Bo, et al.
Publicado: (2015)

Vortioxetine Improved Depressive State In Parkinson’s Disease
por: Yoshimura, Reiji, et al.
Publicado: (2021)

Potential Effect of Vortioxetine on Restless Leg Syndrome
por: Alıcı, Yasemin Hoşgören, et al.
Publicado: (2023)

New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder
por: Katona, Cornelius L, et al.
Publicado: (2014)

Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature
por: Kelliny, Marc, et al.
Publicado: (2015)

The Influence of Pharmacogenetics on the Clinical Relevance of Pharmacokinetic Drug–Drug Interactions: Drug–Gene, Drug–Gene–Gene and Drug–Drug–Gene Interactions
por: Hahn, Martina, et al.
Publicado: (2021)

Vortioxetine as a new frontier in the treatment of chronic neuropathic pain: a review and update
por: Adamo, Daniela, et al.
Publicado: (2021)

Vortioxetine for Cognitive Enhancement in Major Depression: From Animal Models to Clinical Research
por: Bennabi, Djamila, et al.
Publicado: (2019)

The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder
por: Cao, Bing, et al.
Publicado: (2019)

Efficacy of vortioxetine on the physical symptoms of major depressive disorder
por: Christensen, Michael Cronquist, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_rgcurc1ptq1orhp89i3697bkln